TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis TG Therapeutics, Inc. announced the publication of results from a five-year matching-adjusted indirect comparison (MAIC) evaluating long-term relapse activity and disability progression…
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs Bristol Myers Squibb announced positive topline results from the planned interim analysis of the ACTION-1 trial…
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules bioAffinity Technologies, Inc. a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of…
DIC Commences Global Rollout of ECOVART™, a Low Solvent–Content Gravure Ink that Helps Improve Productivity DIC Corporation announced that it will commence the global rollout of gravure ink ECOVART™, which requires the addition of significantly less solvent than conventional gravure…
New Real-World Data for Miach Orthopaedics’ BEAR® Implant Demonstrate Low Retear Rates and Clinically Meaningful Improvements Following ACL Restoration Miach Orthopaedics, Inc., developer of the BEAR® Implant for anterior cruciate ligament (ACL) restoration, announced publication of new two-year results from…
Transcripta Bio & Synfini Collaborate to Identify a Lead Candidate Against a Key Driver of Huntington’s Disease Progression in a Matter of Weeks Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular disease, and Synfini, Inc., an…
Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare Diseases Italfarmaco S.p.A., a global pharmaceutical company with established expertise in histone deacetylase biology and therapeutic development, and VeriSIM Life, an AI-enabled drug discovery and…
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts AstraZeneca announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on the Company’s existing…
Mitsui Chemicals Launches InnoCell™ P-Type High Oxygen-Permeable Culture Plates to Accelerate Organoid-Based Drug Discovery Mitsui Chemicals, Inc. has launched InnoCell™ P-Type, a new adherent cell culture plate in its InnoCell™ series of cell culture ware, as of October 1, 2026.…
NeuWire Medical Announces FDA IDE Approval for STROKE-REWIRE Pivotal Study in Chronic Ischemic Stroke NeuWire Medical announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application for STROKE-REWIRE, a pivotal study evaluating the…
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. announced an exclusive…
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway Summit Therapeutics Inc. announced a clinical trial collaboration agreement with Daiichi Sankyo and AstraZeneca to evaluate ivonescimab, a novel, potential…